Fast measurements of biomolecular interactions

While in electrical engineering, automated measurements may typically take in the order of microseconds to minutes, within bio-engineering, measurements taking hours to days are more common. Hence, technological innovations result in new versions of laptops, tablets, smartphones, etc. every year, while medical innovations leading to new drugs take about 13 years. As a result, drug development is very expensive, entails high risks, and currently does not allow us to deal properly with health emergencies like Ebola, or societal challenges like healthy ageing in times of governmental budget restrictions. But then, what happens if you bring those fields of electrical and bio-engineering together?

At BiosenSource, we aim to drive drug discovery  by developing electronics-based measurement devices and data analysis software that excel in terms of speed, accuracy and user-friendliness

Our first device, called BISense, will allow researchers in academia, biotech and pharma to study interactions between biomolecules, such as protein-DNA, and protein-protein interactions, in a faster and simpler manner than possible today, impacting both fundamental research -i.e., understanding diseases- and drug discovery.

Company history

BiosenSource is a spin-off of imec and VUB that has been founded in November 2015. The company has been incubated at Startit@KBC (October 2014 – March 2016) and won several  business plan competition awards prior to its launch:

  • April 2014: 2nd prize in ‘Battle of Talents’, a business plan competition for students (5 k€).
  • May 2015: 5th prize in Bizidee, a Flemish business plan competition,

Immediately after launch, the firm was selected for the Nano4Health fast track to innovation, an initiative that was part of the European H2020 program. The 30k€ funding received as a part of this track has been invested in the further development of the BISense measuring device; and in June 2016, BiosenSource obtained the Nano4Health award for the project with the highest potential for creating or shaping new value.

In October 2016December 2017 and November 2018, BiosenSource was granted subsequent Flemish subsidies of 10 k€25 k€ and 60 k€ to continue the development of the device.